Quince Therapeutics (NASDAQ:QNCX) Upgraded by Cantor Fitzgerald to “Strong-Buy” Rating

Cantor Fitzgerald upgraded shares of Quince Therapeutics (NASDAQ:QNCX) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

A number of other brokerages have also recently issued reports on QNCX. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Weiss Ratings lowered shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $44.67.

Quince Therapeutics Stock Up 4.4%

QNCX stock opened at $0.97 on Tuesday. Quince Therapeutics has a twelve month low of $0.79 and a twelve month high of $45.50. The company has a market cap of $15.78 million, a PE ratio of -0.09 and a beta of 1.40. The business’s 50-day simple moving average is $1.14 and its 200 day simple moving average is $10.53.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.71.

Hedge Funds Weigh In On Quince Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Quince Therapeutics during the second quarter worth approximately $37,000. GSA Capital Partners LLP grew its position in Quince Therapeutics by 158.0% during the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after acquiring an additional 53,417 shares during the last quarter. Intellectus Partners LLC bought a new stake in Quince Therapeutics during the 4th quarter worth approximately $179,000. Bridgeway Capital Management LLC increased its holdings in Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in Quince Therapeutics during the 4th quarter valued at $213,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.